| Drug Name |
Bivalirudin |
| Drug ID |
BADD_D00279 |
| Description |
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure. |
| Indications and Usage |
For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned. |
| Marketing Status |
approved; investigational |
| ATC Code |
B01AE06 |
| DrugBank ID |
DB00006
|
| KEGG ID |
D03136
|
| MeSH ID |
C074619
|
| PubChem ID |
16129704
|
| TTD Drug ID |
D09HVL
|
| NDC Product Code |
68225-041; 76177-001; 63323-562; 0781-3453; 32861-0001; 52958-112; 55111-918; 55463-0029; 55111-652; 0781-3447; 0781-9158; 36974-0066; 41524-0001; 70511-141; 0781-3158; 65129-1225; 52958-034; 55150-210; 0409-8300; 16729-275; 42023-622; 67457-256; 70860-402; 70860-403; 70436-025; 71288-427; 72572-035 |
| UNII |
TN9BEX005G
|
| Synonyms |
bivalirudin | Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64) | Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen | Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu | CTB-001 | Hirulog | Hirulog-1 | Angiomax | BG 8967 | BG8967 | BG-8967 |
